Transgender women (TGW) face a disproportionately high HIV burden, yet real-world evidence on their engagement in the care cascade is scarce. This study analysed HIV care cascade outcomes and associated factors in a large Argentinian cohort to identify key challenges and inform public health strategies.
Methods
This was a retrospective cohort study of TGW with confirmed HIV linked to care at a public hospital in Buenos Aires (2011–2022). We analyzed 12-month retention in care, antiretroviral therapy (ART) use, and virologic suppression using bivariate and multivariate logistic regression.
Results
Of 240 TGW included, 186 completed 12-months follow-up. The cascade outcomes were: 71.5% retained in care; 87.9% on ART among those retained; and 70.7% virologically suppressed among those on ART. In multivariate analysis, ART initiation at linkage was the strongest predictor of retention (aOR: 35.93; 95%CI: 9.72–132.75), while baseline cocaine use was associated with a lower likelihood of being on ART (aOR: 0.17; 95%CI: 0.04–0.68).
Conclusions
Significant gaps persist in the HIV care cascade for TGW in this real-world setting. While immediate ART initiation is a powerful tool for retention, structural barriers like substance use require integrated interventions. This evidence is critical for designing effective public health strategies to improve health equity.
BaralSDPoteatTStrömdahlS, et al.Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. Lancet Infect Dis2013; 13(3): 214–222.
3.
Dos Ramos FaríasMSGarciaMNReynagaE, et al.First report on sexually transmitted infections among trans (male to female transvestites, transsexuals, or transgender) and male sex workers in Argentina: high HIV, HPV, HBV, and syphilis prevalence. Int J Infect Dis2011; 15(9): e635–e640.
4.
Silva-SantistebanARaymondHFSalazarX, et al.Understanding the HIV/AIDS epidemic in transgender women of Lima, Peru: results from a sero-epidemiologic study using respondent driven sampling. AIDS Behav2012; 16(4): 872–881.
5.
EvensELanhamMSantiK, et al.Experiences of gender-based violence among female sex workers, men who have sex with men, and transgender women in Latin America and the Caribbean: a qualitative study to inform HIV programming. BMC Int Health Hum Right2019; 19(1): 9.
6.
BrennanJKuhnsLMJohnsonAK, et al.Syndemic theory and HIV-related risk among young transgender women: the role of multiple, co-occurring health problems and social marginalization. Am J Publ Health2012; 102(9): 1751–1757.
7.
PoteatTReisnerSLRadixA. HIV epidemics among transgender women. Curr Opin HIV AIDS2014; 9(2): 168–173.
Obedin-MaliverJGoldsmithESStewartL, et al.Lesbian, gay, bisexual, and transgender-related content in undergraduate medical education. JAMA2011; 306(9): 971–977.
10.
ZalazarVArísteguiICardozoN, et al.Factores contextuales, sociales e individuales como barreras y facilitadores para el acceso a la salud de mujeres trans: desde la perspectiva de la comunidad. Actualizaciones en Sida e Infectología2018; 26(98): 1–14.
11.
SocíasMEMarshallBDLArísteguiI, et al.Factors associated with healthcare avoidance among transgender women in Argentina. Int J Equity Health2014; 13(1): 81.
CesarCBlugermanGValienteJA, et al.The HIV care cascade in Buenos Aires, Argentina: results in a tertiary referral hospital. Rev Panam Salud Públic2016; 40(6): 448–454.
World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach: 2010 revision. WHO, 2010. https://www.ncbi.nlm.nih.gov/books/NBK138540/
16.
World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. WHO, 2013. https://www.ncbi.nlm.nih.gov/books/NBK195400/
World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2nd ed.WHO, 2016. ANNEX 10. https://www.ncbi.nlm.nih.gov/books/NBK374293/
19.
FrolaCEAristeguiIFigueroaMI, et al.Retention among transgender women treated with dolutegravir associated with tenofovir/lamivudine or emtricitabine in Argentina: Transviiv study. PLoS One2023; 18(1): e0279996.
ArísteguiIRaduskyPDZalazarV, et al.Impact of the gender identity law in Argentinean transgender women. Int J Transgenderism2017; 18(4): 446–456.
23.
ReisnerSLPlettaDRMayerKH, et al.HIV seropositivity and viral non-suppression in transgender, non-binary, and gender-diverse people in primary care receiving gender-affirming hormone therapy in the USA between 2013 and 2019 (LEGACY): an observational, longitudinal, cohort study. Lancet HIV2025; 12(4): e283–e292.
24.
BagusoGNTurnerCMSantosG-M, et al.Successes and final challenges along the HIV care continuum with transwomen in San Francisco. J Int AIDS Soc2019; 22(4): e25270.
25.
Lacombe-DuncanABauerGRLogieCH, et al.The HIV Care Cascade among transgender women with HIV in Canada: a mixed-methods study. AIDS Patient Care STDS2019; 33(7): 308–322.
26.
MugenyiLNanfukaMByawakaJ, et al.Effect of universal test and treat on retention and mortality among people living with HIV-infection in Uganda: an interrupted time series analysis. PLoS One2022; 17(5): e0268226.
27.
MasukeRKihagaYMashalaM, et al.Twelve months antiretroviral therapy retention among clients newly enrolled to care and treatment services in Geita Region, Tanzania: does universal test and treat matter?Pan Afr Med J2023; 46: 20.
28.
INSIGHT START Study GroupLundgrenJDBabikerAGGordinF, et al.Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med2015; 373(9): 795–807.
29.
MayasiNSituakibanzaHMbulaM, et al.Retention in care and predictors of attrition among HIV-infected patients who started antiretroviral therapy in Kinshasa, DRC, before and after the implementation of the “treat-all” strategy. PLOS Glob Public Health2022; 2(3): e0000259.
30.
MartinsRSKnauthDRVigoA, et al.Marker events associated with adherence to HIV/AIDS treatment in a cohort study. Rev Saude Publica2023; 57: 20.
31.
De BoniRBShepherdBEGrinsztejnB, et al.Substance use and adherence among people living with HIV/AIDS receiving cART in Latin America. AIDS Behav2016; 20(11): 2692–2699.
32.
SharpeTTLeeLMNakashimaAK, et al.Crack cocaine use and adherence to antiretroviral treatment among HIV-infected black women. J Community Health2004; 29(2): 117–127.
33.
SohlerNSlawekDEarnshawV, et al.Drug use and HIV medication adherence in people living with HIV. Subst Abuse2021; 42(3): 310–316.
34.
PoteatTScheimAXavierJ, et al.Global epidemiology of HIV infection and related syndemics affecting transgender people. J Acquir Immune Defic Syndr2016; 72(Suppl 3): S210–S219.
